

7492-104

I hereby certify that this correspondence is being deposited with the U.S. Postal Service First Class Mail in an envelope addressed to: Mail Stop PCT, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313, on the date shown below.

Dated: November 7, 2006

Signature:

Linda J. Werk

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Christopher Martin BUNCE

Application No.: 10/581,376

Confirmation No.
Group Art Unit:

Int'l Filing Date: November 16, 2004

Examiner:

For: BIOLOGICAL CELL CULTURE, CELL
CULTURE MEDIA AND THERAPEUTIC USE
OF BIOLOGICAL CELLS

Mail Stop PCT
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313

CORRECTION OF INTERNATIONAL FILING DATE

Sir:

Enclosed is a copy of the Notification of the International Application Number and of the International Filing Date. Please note that the International Filing Date has been corrected to **November 16, 2004**. We are also enclosing a copy of the "Corrected Version" of the published PCT specification indicating that the international filing date was indeed November 16, 2004.

Dated: November 7, 2006

Respectfully submitted,

By _____ 
Robert Berliner, Reg. No. 20,121
Attorneys for Applicant

BERLINER & ASSOCIATES
555 West Fifth Street, 31st Floor
Los Angeles, CA 90013
(213) 533-4171
(213) 533-4174 (Fax)

PATENT COOPERATION TREATY

From the RECEIVING OFFICE

To:

Marks & Clerk
Alpha Tower
Suffolk Street Queensway
Birmingham

B1 1TT

PCT

**NOTIFICATION OF THE INTERNATIONAL
APPLICATION NUMBER AND OF THE
INTERNATIONAL FILING DATE**

(PCT Rule 20.5(c))

Applicant's or agent's file reference
W072537PPC

Date of mailing
(day/month/year)

08-12-04

IMPORTANT NOTIFICATION

International application No.
PCT/GB2004/004826

International filing date (day/month/year)
16/11/2004

Priority date (day/month/year)
05/12/2003

Applicant

The University of Birmingham et al

Title of the invention

Biological Cell Culture, Cell Culture Media and Therapeutic Use of Biological Cells

1. The applicant is hereby notified that the international application has been accorded the international application number and the international filing date indicated above.

2. The applicant is further notified that the record copy of the international application:



was transmitted to the International Bureau on 08-12-04



has not yet been transmitted to the International Bureau for the reason indicated below and a copy of this notification has been sent to the International Bureau*:



because the necessary national security clearance has not yet been obtained.



because (reason to be specified):

* The International Bureau monitors the transmittal of the record copy by the receiving Office and will notify the applicant (with Form PCT/IB/301) of its receipt. Should the record copy not have been received by the expiration of 14 months from the priority date, the International Bureau will notify the applicant (Rule 22.1(c)).

Name and mailing address of the receiving Office

The Patent Office
Cardiff Road, Newport
South Wales NP10 8QQ

Facsimile No.

Authorized officer

Kelly Sheppard

Telephone No. 01633 813767

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
23 June 2005 (23.06.2005)

PCT

(10) International Publication Number
WO 2005/056780 A3

(51) International Patent Classification:
CI2N 5/00 (2006.01) *A61K 35/12* (2006.01)
CI2N 5/06 (2006.01)

(21) International Application Number:
PCT/GB2004/004826

(22) International Filing Date:
16 November 2004 (16.11.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0328245.6 5 December 2003 (05.12.2003) GB

(71) Applicant (*for all designated States except US*): THE UNIVERSITY OF BIRMINGHAM [GB/GB]; Edgbaston, Birmingham B15 2TT (GB).

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): BUNCE, Christopher, Martin [GB/GB]; Shool of Biosciences, The University of Birmingham, Edgbaston, Birmingham B15 2TT (GB).

(74) Agents: WARD, David, I. et al.; Marks & Clerk, Alpha Tower, Suffolk Street Queensway, Birmingham B1 1TT (GB).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM,

AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
28 July 2005

(48) Date of publication of this corrected version:
5 October 2006

(15) Information about Correction:
see PCT Gazette No. 40/2006 of 5 October 2006

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CELL CULTURE WITH NM23, CELL CULTURE MEDIA COMPRISING NM23 AND THERAPEUTIC USE OF CELLS CULTURED IN THE PRESENCE OF NM23.

(57) Abstract: The protein NM23 is disclosed as an agent for the maintenance of undifferentiated biological cells in culture. The NM23 protein may act as a survival factor for such cultured cells, or to prevent the differentiation and maturation of the cultured cells. The use of NM23 protein is applicable to culture of stem and/or progenitor cells, and particularly to such cells cultured and adapted for therapeutic use. The invention provides methods, media and media supplements for use in the culture of biological cells, and further provides methods of preparing biological cells for therapeutic use, as well as methods of therapy utilising biological cells and medicaments comprising biological cells adapted for therapeutic use.

A3

WO 2005/056780